Literature DB >> 19552682

A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder.

C Hermans1, C Wittevrongel, C Thys, P A Smethurst, C Van Geet, K Freson.   

Abstract

BACKGROUND: The physiological relevance of the collagen glycoprotein VI (GPVI) receptor was known prior to its recognition as a platelet membrane receptor as several patients lacking GPVI as a consequence of autoantibody inhibition presented with a mild bleeding diathesis. Remarkably, patients with a proven GPVI gene mutation have not yet been identified.
RESULTS: In the present study, we describe a patient with a lifelong history of bleeding problems, structurally normal platelets but a functional platelet defect. Platelet aggregations are normal except for an absent response to Horm collagen, convulxin and the collagen-related peptide (CRP). ATP dense granule secretion is normal with ADP but absent with Horm collagen. Thrombus formation on a collagen surface in flowing blood is reduced but more single platelets are attached. Remarkably, the platelet function analyzer-100 shows a shortened collagen/ADP closure time. Flow cytometry demonstrates an absent expression of GPVI whereas immunoblot analysis shows strongly reduced levels of GPVI. The patient is compound heterozygous for an out-of-frame 16-bp deletion and a missense mutation S175N in a highly conserved residue of the 2nd Ig-like GPVI domain. The parents without clinical bleeding problems are heterozygous carriers. The mother carries the S175N mutation and presents with a mild functional platelet defect. In vitro studies show a reduced membrane expression and convulxin binding with the mutated S175N compared with the wild-type (WT) GPVI receptor.
CONCLUSIONS: This study presents the first patient with a proven genetic GPVI defect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19552682     DOI: 10.1111/j.1538-7836.2009.03520.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

Review 1.  Extracellular matrix proteins in hemostasis and thrombosis.

Authors:  Wolfgang Bergmeier; Richard O Hynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 2.  Platelet receptor signaling in thrombus formation.

Authors:  David Stegner; Bernhard Nieswandt
Journal:  J Mol Med (Berl)       Date:  2010-11-07       Impact factor: 4.599

Review 3.  Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.

Authors:  Yacine Boulaftali; Paul R Hess; Mark L Kahn; Wolfgang Bergmeier
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

4.  Platelet ITAM signaling is critical for vascular integrity in inflammation.

Authors:  Yacine Boulaftali; Paul R Hess; Todd M Getz; Agnieszka Cholka; Moritz Stolla; Nigel Mackman; A Phillip Owens; Jerry Ware; Mark L Kahn; Wolfgang Bergmeier
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

5.  Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel.

Authors:  Ban B Dawood; Gillian C Lowe; Marie Lordkipanidzé; Danai Bem; Martina E Daly; Mike Makris; Andrew Mumford; Jonathan T Wilde; Steve P Watson
Journal:  Blood       Date:  2012-09-21       Impact factor: 22.113

6.  A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.

Authors:  Ernest Turro; Daniel Greene; Anouck Wijgaerts; Chantal Thys; Claire Lentaigne; Tadbir K Bariana; Sarah K Westbury; Anne M Kelly; Dominik Selleslag; Jonathan C Stephens; Sofia Papadia; Ilenia Simeoni; Christopher J Penkett; Sofie Ashford; Antony Attwood; Steve Austin; Tamam Bakchoul; Peter Collins; Sri V V Deevi; Rémi Favier; Myrto Kostadima; Michele P Lambert; Mary Mathias; Carolyn M Millar; Kathelijne Peerlinck; David J Perry; Sol Schulman; Deborah Whitehorn; Christine Wittevrongel; Marc De Maeyer; Augusto Rendon; Keith Gomez; Wendy N Erber; Andrew D Mumford; Paquita Nurden; Kathleen Stirrups; John R Bradley; F Lucy Raymond; Michael A Laffan; Chris Van Geet; Sylvia Richardson; Kathleen Freson; Willem H Ouwehand
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

7.  Glycoprotein VI Blockade: Not Just Targeting Collagen Anymore?

Authors:  Shuchi Gupta; Lawrence F Brass
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-26       Impact factor: 8.311

8.  Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood.

Authors:  Stephanie M Jung; Masaaki Moroi; Kenji Soejima; Tomohiro Nakagaki; Yoshiki Miura; Michael C Berndt; Elizabeth E Gardiner; Joanna-Marie Howes; Nicholas Pugh; Dominique Bihan; Steve P Watson; Richard W Farndale
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

9.  GPVI (Glycoprotein VI) Interaction With Fibrinogen Is Mediated by Avidity and the Fibrinogen αC-Region.

Authors:  Rui-Gang Xu; Julia S Gauer; Stephen R Baker; Alexandre Slater; Eleyna M Martin; Helen R McPherson; Cédric Duval; Iain W Manfield; Arkadiusz M Bonna; Steve P Watson; Robert A S Ariëns
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-21       Impact factor: 8.311

10.  Fibrin activates GPVI in human and mouse platelets.

Authors:  Osama M Alshehri; Craig E Hughes; Samantha Montague; Stephanie K Watson; Jon Frampton; Markus Bender; Steve P Watson
Journal:  Blood       Date:  2015-08-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.